Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian C Betts

Showing results (31-40 of 57) with videos related to

Pageof 6
Sort By:
The Journal of Clinical Investigation|May 22, 2020
Human CD83-targeted chimeric antigen receptor T cells prevent and treat graft-versus-host diseaseBishwas Shrestha, Kelly Walton, Jordan Reff, et al.
Blood|April 19, 2012
Human Langerhans cells use an IL-15R-α/IL-15/pSTAT5-dependent mechanism to break T-cell tolerance against the self-differentiation tumor antigen WT1Emanuela Romano, Jesse W Cotari, Rosa Barreira da Silva, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 26, 2015
Ofatumumab in combination with glucocorticoids for primary therapy of chronic graft-versus-host disease: phase I trial resultsJoseph Pidala, Jongphil Kim, Brian C Betts, et al.
Journal of the Neurological Sciences|January 30, 2026
Pretreatment physical function as a risk factor for movement and neurocognitive treatment-emergent events (MNTs) in multiple myeloma (MM) patients treated with cilta-celMegan M Herr, Nisha M Nair, Theresa Hahn, et al.
Haematologica|April 5, 2015
Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host diseaseJoseph Pidala, Jongphil Kim, Melissa Alsina, et al.
JCI Insight|August 9, 2019
Stress responses, M2 macrophages, and a distinct microbial signature in fatal intestinal acute graft-versus-host diseaseShernan G Holtan, Ashraf Shabaneh, Brian C Betts, et al.
Transplantation and Cellular Therapy|June 6, 2023
Phase II, Open-Label Clinical Trial of Urinary-Derived Human Chorionic Gonadotropin/Epidermal Growth Factor for Life-Threatening Acute Graft-versus-Host DiseaseShernan G Holtan, Andrea Hoeschen, Qing Cao, et al.
Blood Advances|January 27, 2026
Targeting Aurora Kinase A to Prevent GVHD and Relapse after Myeloablative Allogeneic Hematopoietic Cell TransplantationShernan G Holtan, Punita Grover, Kelly Walton, et al.
Bone Marrow Transplantation|January 9, 2021
Outcomes of chronic graft-versus-host disease following matched sibling donor versus umbilical cord blood transplantGrigori Okoev, Daniel J Weisdorf, John E Wagner, et al.
Transplantation and Cellular Therapy|December 15, 2025
HIGHER HLA-DRB1 EVOLUTIONARY DIVERGENCE (HED) IS ASSOCIATED WITH REDUCED RELAPSE AND IMPROVED SURVIVAL AFTER MATCHED UNRELATED HEMATOPOIETIC CELL TRANSPLANTATIONJennifer N Saultz, Yung-Tsi Bolon, Tao Wang, et al.
Pageof 6

Showing results (31-40 of 57) with videos related to

Sort By:
Pageof 6
The Journal of Clinical Investigation|May 22, 2020
Human CD83-targeted chimeric antigen receptor T cells prevent and treat graft-versus-host diseaseBishwas Shrestha, Kelly Walton, Jordan Reff, et al.
Blood|April 19, 2012
Human Langerhans cells use an IL-15R-α/IL-15/pSTAT5-dependent mechanism to break T-cell tolerance against the self-differentiation tumor antigen WT1Emanuela Romano, Jesse W Cotari, Rosa Barreira da Silva, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 26, 2015
Ofatumumab in combination with glucocorticoids for primary therapy of chronic graft-versus-host disease: phase I trial resultsJoseph Pidala, Jongphil Kim, Brian C Betts, et al.
Journal of the Neurological Sciences|January 30, 2026
Pretreatment physical function as a risk factor for movement and neurocognitive treatment-emergent events (MNTs) in multiple myeloma (MM) patients treated with cilta-celMegan M Herr, Nisha M Nair, Theresa Hahn, et al.
Haematologica|April 5, 2015
Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host diseaseJoseph Pidala, Jongphil Kim, Melissa Alsina, et al.
JCI Insight|August 9, 2019
Stress responses, M2 macrophages, and a distinct microbial signature in fatal intestinal acute graft-versus-host diseaseShernan G Holtan, Ashraf Shabaneh, Brian C Betts, et al.
Transplantation and Cellular Therapy|June 6, 2023
Phase II, Open-Label Clinical Trial of Urinary-Derived Human Chorionic Gonadotropin/Epidermal Growth Factor for Life-Threatening Acute Graft-versus-Host DiseaseShernan G Holtan, Andrea Hoeschen, Qing Cao, et al.
Blood Advances|January 27, 2026
Targeting Aurora Kinase A to Prevent GVHD and Relapse after Myeloablative Allogeneic Hematopoietic Cell TransplantationShernan G Holtan, Punita Grover, Kelly Walton, et al.
Bone Marrow Transplantation|January 9, 2021
Outcomes of chronic graft-versus-host disease following matched sibling donor versus umbilical cord blood transplantGrigori Okoev, Daniel J Weisdorf, John E Wagner, et al.
Transplantation and Cellular Therapy|December 15, 2025
HIGHER HLA-DRB1 EVOLUTIONARY DIVERGENCE (HED) IS ASSOCIATED WITH REDUCED RELAPSE AND IMPROVED SURVIVAL AFTER MATCHED UNRELATED HEMATOPOIETIC CELL TRANSPLANTATIONJennifer N Saultz, Yung-Tsi Bolon, Tao Wang, et al.
Pageof 6